Ascendis Pharma (NasdaqGS:ASND) has drawn investor attention after recent trading left the stock around $251.76, with short term moves mixed but positive over the past month and the past 3 months.
See our latest analysis for Ascendis Pharma.
That recent pullback, including a 1 day share price return of 3.54% and a 7 day share price return of 5.08%, comes after a 30 day share price return of 9.07% and a 90 day share price return of 4.77%. This suggests Ascendis Pharma’s momentum has cooled slightly following a stronger short term run.
If you are weighing Ascendis Pharma against other healthcare opportunities, this could be a useful moment to scan a wider field of specialized biotech peers through 39 healthcare AI stocks
Ascendis Pharma now trades around $251.76, at roughly a 20% discount to the average analyst target and a much larger gap to some intrinsic value estimates. Is this genuine mispricing, or a clear signal that market caution has a point?
Most Popular Narrative: 14.3% Undervalued
On the most followed narrative, Ascendis Pharma’s fair value of $293.79 sits meaningfully above the recent $251.76 share price, which puts the company’s rare disease platform in sharp focus.
Expansion of SKYTROFA into additional established growth hormone indications such as ISS, SHOX deficiency, Turner syndrome and SGA, alongside potential use in new segments like achondroplasia, can increase total addressable demand and contribute to higher revenue and more efficient use of existing commercial infrastructure.
Want to see what revenue curve, margin profile and earnings multiple sit behind that $293.79 figure? The core story blends rapid top line expansion with premium profitability assumptions baked into a discounted cash flow model using a 7.09% rate and a future earnings profile that looks very different to today.
Result: Fair Value of $293.79 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Ascendis Pharma story also carries real execution risks, particularly if Yorvipath uptake slows or if TransCon CNP approvals and rollout progress more slowly than analysts expect.
Find out about the key risks to this Ascendis Pharma narrative.
Another View on Ascendis Pharma’s Valuation
The earlier fair value of $293.79 for Ascendis Pharma comes from analyst earnings and DCF style assumptions, but the current P/E tells a different story. At 27.6x earnings, the stock trades above the US Biotechs industry average of 17.3x, yet below a 38.6x peer average. That mix of premium and discount raises a simple question: is the real risk that expectations are too high, or that they are still too low?
To see how this earnings based view stacks up against a fuller intrinsic value approach, it is worth looking at how the SWS DCF model frames Ascendis Pharma’s future cash flows, return hurdles and implied fair value, then comparing both sets of assumptions side by side. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed sentiment around Ascendis Pharma’s valuation, risks and rewards, move quickly, review the full picture and weigh the 3 key rewards and 2 important warning signs
Looking For More Ideas Beyond Ascendis Pharma?
If Ascendis Pharma has sharpened your focus on risk, return and valuation, do not stop here. There are other opportunities worth putting on your radar.
- Spot potential value opportunities early by reviewing the 45 high quality undervalued stocks, which combines quality fundamentals with pricing that may appeal to disciplined investors.
- Prioritize resilience and sleep better at night by checking companies in the 80 resilient stocks with low risk scores with comparatively lower overall risk profiles.
- Hunt for potential future standouts before the crowd by scanning the screener containing 20 high quality undiscovered gems that pair solid financials with underfollowed stories.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com